Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

9536 ARTÍCULOS , VIENDO DEL 7366 AL 7380

The taxonomy of primary progressive aphasia: it walks and quacks like a duck ... but which duck?

Drachman DA.

Neurology. 2011 Mar 15;76(11):942-3. doi: 10.1212/WNL.0b013e3182104130. Epub 2011 Feb 16.

Amitriptyline and lorazepam improved catatonia and occipital hypoperfusion in a patient with DLB

Maeda K, Ogawa N.

Intern Med. 2011;50(4):363-6. doi: 10.2169/internalmedicine.50.4512. Epub 2011 Feb 15.

Antidepressants for agitation and psychosis in dementia

Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P.

Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD008191. doi: 10.1002/14651858.CD008191.pub2.

Systems biology of Alzheimer's disease: how diverse molecular changes result in memory impairment in AD

Juhász G, Földi I, Penke B.

Neurochem Int. 2011 Jun;58(7):739-50. doi: 10.1016/j.neuint.2011.02.008. Epub 2011 Feb 17.

A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease

Burns A, Perry E, Holmes C, Francis P, Morris J, Howes MJ, Chazot P, Lees G, Ballard C.

Dement Geriatr Cogn Disord. 2011;31(2):158-64. doi: 10.1159/000324438. Epub 2011 Feb 19.

DTI studies in patients with Alzheimer's disease, mild cognitive impairment, or normal cognition with evaluation of the intrinsic background gradients

Jahng GH, Xu S, Weiner MW, Meyerhoff DJ, Park S, Schuff N.

Neuroradiology. 2011 Oct;53(10):749-62. doi: 10.1007/s00234-011-0845-3. Epub 2011 Feb 22.

Inflammatory risk factors and pathologies associated with Alzheimer's disease

Sastre M, Richardson JC, Gentleman SM, Brooks DJ.

Curr Alzheimer Res. 2011 Mar;8(2):132-41. doi: 10.2174/156720511795256062.

Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies

Anstey KJ, Cherbuin N, Budge M, Young J.

Obes Rev. 2011 May;12(5):e426-37. doi: 10.1111/j.1467-789X.2010.00825.x. Epub 2011 Feb 23.

Sublingual sufentanil for incident pain and dementia-related response agitation

Passmore MJ.

Int Psychogeriatr. 2011 Jun;23(5):844-6. doi: 10.1017/S1041610211000275. Epub 2011 Feb 25.

Depressive symptoms, brain volumes and subclinical cerebrovascular disease in postmenopausal women: the Women's Health Initiative MRI Study

Goveas JS, Espeland MA, Hogan P, Dotson V, Tarima S, Coker LH, Ockene J, Brunner R, Woods NF, Wassertheil-Smoller S, Kotchen JM, Resnick S.

J Affect Disord. 2011 Jul;132(1-2):275-84. doi: 10.1016/j.jad.2011.01.020. Epub 2011 Feb 24.

Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease

Honea RA, Swerdlow RH, Vidoni ED, Burns JM.

Neurology. 2011 Mar 1;76(9):822-9. doi: 10.1212/WNL.0b013e31820e7b74.

Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia

Walther S, Schüpbach B, Seifritz E, Homan P, Strik W.

J Clin Psychopharmacol. 2011 Apr;31(2):256-8. doi: 10.1097/JCP.0b013e31820e861c.

[Prenatal infection as driving force of aging-associated neurodegenerative diseases]

Knuesel I.

Praxis (Bern 1994). 2011 Mar 2;100(5):299-304. doi: 10.1024/1661-8157/a000451.

Anatomy of language impairments in primary progressive aphasia

Rogalski E, Cobia D, Harrison TM, Wieneke C, Thompson CK, Weintraub S, Mesulam MM.

J Neurosci. 2011 Mar 2;31(9):3344-50. doi: 10.1523/JNEUROSCI.5544-10.2011.

Cognitive lifestyle and long-term risk of dementia and survival after diagnosis in a multicenter population-based cohort

Valenzuela M, Brayne C, Sachdev P, Wilcock G, Matthews F; Medical Research Council Cognitive Function and Ageing Study.

Am J Epidemiol. 2011 May 1;173(9):1004-12. doi: 10.1093/aje/kwq476. Epub 2011 Mar 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias